The SURPASS-1 through SURPASS-5 trials demonstrated that 91% of patients on tirzepatide achieved an A1C below 7% (the standard treatment target), compared to approximately 68% on liraglutide in comparable studies
Con: Requires regular injections, which may not be ideal for everyone
I have seen patients recover
This was evident when testing preference for low (0.2%) but not high (2%) concentrations of sucrose solutions (Supplementary Figure 4)
For Dementia Patients Despite some promise from early clinical trials, a meta-analysis of clinical trials concluded that ALCAR supplements are unlikely to provide a clinically meaningful benefit on the cognitive, behavioral, or functional abilities of Alzheimer's patients [1]
Rather than testing these agents individually, researchers use the blend to observe cross-talk between different receptor groups